which is cutting costs amid doubts about its ability to remain in business and plummeting demand for Covid products worldwide. In 2022, Novavax terminated a purchase agreement with Geneva-based Gavi.

This decision follows the positive opinion from the Committee for Medicinal Products fo Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M ...

and if approved by the Medicines and Healthcare products Regulatory Agency (MHRA) a large proportion of those supplies will be manufactured at Novavax’ UK factory in Billingham, Stockton-on-Tees.

Novavax shares are trading lower by 9.8% during Monday's session. Shares of vaccine stocks are trading lower after Moderna ...

Novavax shares are trading lower by 9.8% during Monday's session. Shares of vaccine stocks are trading lower after Moderna issued 2025 revenue guidance below analyst estimates. Novavax shares ...

Shares of Novavax (NVAX) have gained 3.5% over the past four weeks to close the last trading session at $8.81, but there could still be a solid upside left in the stock if short-term price targets ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

In this article, we are going to take a look at where Novavax, Inc. (NYSE:NVAX) stands against other under-the-radar stocks. Investing in under-the-radar stocks can be a savvy move for those ...

Shares of Novavax Inc. NVAX inched 0.57% higher to $8.82 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.77% ...

The average of price targets set by Wall Street analysts indicates a potential upside of 81.6% in Novavax (NVAX). While the effectiveness of this highly sought-after metric is questionable, the ...